Advertisement

U.S. FDA advisors back bivalent COVID vaccine for initial series, boosters

Click to play video: 'WHO committee to discuss whether COVID-19 still global emergency'
WHO committee to discuss whether COVID-19 still global emergency
World Health Organization director general Tedros Adhanom Ghebreyesus said on Monday that this week, the emergency COVID-19 committee will meet to discuss whether the current situation still constitutes a global emergency – Jan 24, 2023

Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of targeting the same coronavirus strain for initial COVID-19 vaccine doses and boosters going forward, but some expressed skepticism about whether all Americans need to receive the shots annually.

The agency is trying to simplify its COVID-19 vaccine policy as it considers whether to recommend Americans get an annual booster shot for the virus. But several members of the expert advisory group asked for more robust data on benefits of annual shots for younger, healthier people.

“We’re in a very different place. We have a lot of population immunity,” said Hayley Gans, professor of pediatrics at Stanford University Medical Center. “Now that people are immune, how long does that last?”

Story continues below advertisement

Vaccine makers Pfizer Inc PFE.N with partner BioNTech SE 22UAy.DE and Moderna Inc MRNA.O introduced late last year updated versions of their COVID vaccines tailored to target Omicron variants as well as the original coronavirus. In the United States, those were used only as booster shots.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

The FDA advisory group unanimously backed using those shots for the primary series for those who have yet to be vaccinated against COVID-19 as well.

The FDA said it envisioned holding a meeting later in the year to determine the composition of shots for the fall, although some vaccine makers might be able to produce updated shots more quickly.

Click to play video: 'The latest on the spread of the new COVID variant in Canada'
The latest on the spread of the new COVID variant in Canada

Pfizer/BioNTech and Moderna were able to produce the currently available messenger RNA boosters in about three months last year, but Novavax Inc NVAX.O said on Thursday it would require six months to make a new version of its protein-based COVID-19 vaccine designed to match circulating coronavirus variants.

Story continues below advertisement

FDA would consider an earlier timeline for vaccines like Novavax’s following the company’s manufacturing assessment, Peter Marks, director of the agency’s Center for Biologics Evaluation & Research, said.

Health officials in the Biden administration have suggested that annual, updated COVID-19 booster shots could provide a high level of protection against severe disease.

(Reporting by Leroy Leo in Bengaluru, Michael Erman in Maplewood, New Jersey; Editing by Bill Berkrot)

Sponsored content

AdChoices